[{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","commit":"925a04b429","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a third batch of thirty approved products","file":"src/data/spikes/sarcoma.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ifosfamide\" }]"}]},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/sarcoma.ts","type":"changed","fields":[{"field":"tldr","before":"\"An alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.\"","after":"\"Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.\""}]},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","commit":"2997dc2520","date":"2026-09-08","author":"Jude Gomila","message":"Deep cancer spikes: DLBCL, multiple myeloma, Hodgkin lymphoma, sarcoma, neuroblastoma (135 new entities with structured outcomes, dosing, to","file":"src/data/spikes/sarcoma.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"technologies"},{"field":"cancers"}]}]